Pasadena, California, August 19, 2015 (Newswire.com) - As part of a round table discussion to highlight some of the region’s successes Rep. Judy Chu (CA-27) invited U.S. Small Business Administrator Maria Contreras-Sweet to meet with Stephen Fiacco, co-founder and CEO of EvoRx, a four year old biotech company focused on the discovery and development of novel treatment options for patients with serious illnesses.
"It was a tremendous pleasure to meet both Rep. Chu and Administrator Contreras-Sweet and show how immensely important initiatives such as the Small Business Administration’s SBIR program is to young companies such as ours. I am hoping that we were able to show who the people are behind the grant application and to put a human face on the impact these initiatives can have. These initiatives not only further innovation, products, and help patients, but give real jobs to real people" said Stephen Fiacco.
Rep. Chu was instrumental in advocating for the renewal of the program, which the House voted on to increase authorization on July 27th. “Young entrepreneurs such as Stephen Fiacco are vital to the growth of our region and the strength of our economy,” she said. “We need to be committed to support their endeavors with concrete and tangible incentives, like SBA's 7(a) and SBIR programs, so we can retain our local talent and make biotech and high-tech a permanent fixture in Pasadena and the San Gabriel Valley.”
For more information on Rep. Chu's visit at http://chu.house.gov/press-release/rep-chu-hosts-roundtable-us-small-business-administrator-and-local-small-business
About EvoRx - Founded in 2011, EvoRx is a privately held, early stage biotechnology company. It strives to discover and develop innovative peptide therapeutics and targeted radio-pharmaceuticals for treatment and diagnosis of disease with high unmet medical need. Its proprietary Evo-Link technology rapidly generates remarkably high diversity cyclic peptide libraries. The libraries are screened for drug-like activity in environments that mimic the physiological environment of the body. The result is uniquely structured peptides that are highly stable in human serum, that have antibody-like specificity and affinity, and that are also membrane permeable. These features allow for targeting protein interactions, previously thought of as “undruggable”. For more information, visit www.evorxtechnologies.com.
Share: